

## Consultation workshop | Advanced therapies

### Agenda

29.09.2016 • IMI Stakeholder Forum

Hotel Crowne Plaza Le Palace • Rue Gineste 3 • Brussels, Belgium

This workshop will provide an introduction to advanced therapies and what IMI has done so far on this. It will provide an update on IMI's recent consultation on the subject, and seek to gain further feedback from stakeholders on what could be done and where the gaps are. Ultimately, the goal is to deliver some concrete ideas for potential IMI projects in this area that could form part of future IMI Calls for proposals.

8:30 – 09:00 *Registration & networking breakfast*

**09:00 – 9:30** **Opening session** *Ballroom*

Pierre Meulien, IMI Executive Director

**09:30 – 10:15** **Introduction to advanced therapies** *Ballroom*

Alain Fischer, Professor at Collège de France; Paris Public Hospitals Group (AP-HP); Imagine Institute

**10:15 – 10:30** **Broad overview of the outcomes of the consultation** *Ballroom*

Pierre Meulien, IMI Executive Director

10:30 – 11:00 *Coffee break*

**11:00 – 12:15** **Discussion: the scientific challenges – pre-clinical, clinical and manufacturing** *Ballroom*

Mimoun Azzouz, Professor of Translational Neuroscience, University of Sheffield

Wilfried Dalemans, Chief Technical Officer, TiGenix

Alain Fischer, Collège de France; Paris Public Hospitals Group (AP-HP); Imagine Institute

Michael Hudecek, Research group leader, CAR T, department of medicine II, Universitätsklinikum Würzburg

Georg Terstappen, Head of Discovery Biology, AbbVie

*Moderated by Salah-Dine Chibout, Novartis*

12:15 – 13:15 *Lunch break*

**13:15 – 14:30** **Discussion: the regulatory and market access challenges** *Ballroom*

Arnd Hoeveler, Head of Unit, Innovative tools, technologies and concepts in health research, DG Research & Innovation, European Commission

Carole Longson, Executive Director, National Institute for Health and Care Excellence (NICE); IMI Scientific Committee

Rocio Salvador Roldan, Policy officer, Medicines: policy, authorisation and monitoring, DG Health and Food Safety, European Commission

Chris Sotirelis, UK Thalassaemia Society, European Organisation for Rare Diseases (EURORDIS)

*Moderated by Magda Gunn, IMI Programme Office*

**14:30 – 16:00**

**Presentation of IMI topic ideas and feedback from stakeholders**

*Ballroom*

Magda Papadaki, Association of the British Pharmaceutical Industry (ABPI)

Wilfried Dalemans, TiGenix

Luc Kupers, Genzyme

*Chaired by Georg Terstappen, AbbVie*

**16:00 – 17:00**

**IMI Stakeholder Forum concluding remarks**

*Ballroom*

Feedback from *rapporteurs* of parallel sessions

Conclusions by Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University; Chair of the IMI Scientific Committee

17:00

*End of the event*